BioCentury
ARTICLE | Clinical News

Pfizer planning Phase III for DMD gene therapy, close on Sarepta's heels

June 28, 2019 10:53 PM UTC

Undeterred by two patient hospitalizations revealed in Phase Ib data Friday for its DMD gene therapy, Pfizer is moving forward with plans for a Phase III trial start in 1H20, setting up a tight race to the finish line between it and Sarepta.

Pfizer Inc. (NYSE:PFE) said at the Parent Project Muscular Dystrophy (PPMD) Connect meeting in Orlando its Duchenne muscular dystrophy (DMD) gene therapy PF-06939926 resulted in two hospitalizations among six patients treated...

BCIQ Target Profiles

Dystrophin